TL;DR
This study investigated Magnetic Seizure Therapy (MST) as an alternative to Electroconvulsive Therapy (ECT) for schizophrenia. While both treatments showed comparable efficacy in reducing psychotic symptoms, MST resulted in significantly less cognitive impairment, particularly in memory and language functions, suggesting it's a promising alternative for patients with schizophrenia.
What Problem Does This Paper Address?
Schizophrenia is a severe mental disorder characterized by significant cognitive, behavioral, and emotional dysfunction, leading to considerable disability and economic burden. While antipsychotics are the primary treatment, a substantial portion of patients do not respond fully. Electroconvulsive Therapy (ECT) is an established treatment option for severe mental disorders when pharmacotherapy is insufficient, but it's associated with cognitive side effects like amnesia and disorientation. Magnetic Seizure Therapy (MST) has emerged as a potential alternative to ECT, aiming to induce therapeutic seizures with magnetic pulses that can be more focally targeted than electrical currents. However, research on MST's efficacy and safety in schizophrenia, especially in regions where ECT is commonly used, has been limited. This paper addresses this gap by directly comparing MST and ECT in patients with schizophrenia through a randomized controlled trial, focusing on both clinical and cognitive outcomes.
Methods
The study employed a double-blind, parallel randomized controlled trial (RCT) design. 79 inpatients diagnosed with schizophrenia according to DSM-5 criteria were recruited and randomized in a 1:1 ratio to receive either 10 sessions of Magnetic Seizure Therapy (MST) or Electroconvulsive Therapy (ECT) over four weeks. Treatment was administered under general anesthesia with muscle relaxants.
- MST Procedure: Utilized a MagPro MST device with a twin coil, delivering magnetic pulses at 50 Hz and 100% output. A titration method was used to determine the optimal stimulation duration, starting at 4s and increasing up to 20s per session, with adjustments made based on seizure quality.
- ECT Procedure: Employed bitemporal ECT using a Thymatron System IV device with a pulse width of 0.5 ms. Energy levels were adjusted based on patient age and increased by 5% in subsequent sessions.
- Assessments: Both groups received clinical and cognitive assessments at baseline and after the four-week treatment period.
- Clinical Outcome: Assessed using the Positive and Negative Syndrome Scale (PANSS) to measure symptom severity.
- Cognitive Outcome: Evaluated using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), which measures immediate memory, visuospatial function, language, attention, and delayed memory. RBANS was chosen for its feasibility in patients with severe psychosis.
- Statistical Analysis: The study used both per-protocol (PP) and intention-to-treat (ITT) analyses. Statistical methods included chi-square tests, independent t-tests, Mann-Whitney U tests, and full factorial linear mixed-effect models (LMEs) to analyze within-group and between-group effects. Effect sizes were calculated using Hedge's g for continuous variables and relative risk (RR) for dichotomous variables.
Datasets
The study utilized data collected from 79 inpatients diagnosed with schizophrenia at the Shanghai Mental Health Center. No new datasets or benchmarks were introduced.
Key Insights and Ideas
- MST as a Viable Alternative: The study provides strong evidence that MST is a comparable alternative to ECT for treating psychotic symptoms in schizophrenia, without compromising efficacy.
- Cognitive Preservation with MST: The most striking finding is MST's significantly better cognitive profile compared to ECT. This suggests that the more focal nature of magnetic stimulation may spare brain regions crucial for cognitive functions, unlike the broader electrical stimulation of ECT.
- Differential Impact on Cognitive Domains: MST showed a clear advantage in preserving immediate memory, language function, and overall cognitive function. This is particularly important as cognitive deficits are a core feature of schizophrenia and significantly impact functional recovery.
- Predictors of Response: Baseline cognitive performance emerged as a key predictor for both MST and ECT response, highlighting the importance of preserving cognitive function for treatment success. Shorter disease duration and non-clozapine resistance were also predictive of MST response.
- Safety Profile: Both MST and ECT were generally well-tolerated, with no serious adverse events reported that were definitively attributable to the seizure therapy itself, although some adverse events were noted and managed.
Key Results
- Antipsychotic Efficacy: Both MST and ECT significantly reduced psychotic symptoms (PANSS scores) in the ITT and PP analyses. Direct comparisons showed no significant differences in antipsychotic effect between the two groups. The response rate was comparable, with MST showing a slightly higher, though not statistically significant, response rate.
- Cognitive Outcomes:
- Less Cognitive Impairment with MST: MST demonstrated significantly less cognitive impairment compared to ECT across several domains. Specifically, MST showed significant improvements (or less decline) in immediate memory (g = 1.26), language function (g = 1.14), delayed memory (g = 0.75), and global cognitive function (g = 1.07) in the per-protocol analysis.
- ITT vs. PP: While the ITT analysis showed similar trends, the difference in delayed memory was not statistically significant, likely due to missing data.
- Adverse Events: The study reported some adverse events, including liver dysfunction, conjunctiva hemorrhage, and arm swelling, but these were generally mild and resolved.
Limitations and Future Work
The authors acknowledge several limitations:
- Small Sample Size: The study was prematurely suspended due to coil malfunction, resulting in a smaller than planned sample size. This limited the power to conduct non-inferiority analyses and potentially detect smaller differences between MST and ECT.
- Baseline Imbalances: Minor imbalances in baseline psychotic symptom severity and immediate memory between groups may have influenced the results.
- Confounding Factors: The use of various antipsychotic medications and dosages, while standardized using the defined daily dose (DDD) approach, could still act as confounders.
- Limited Follow-up: Only one follow-up assessment was conducted, which may not fully capture long-term cognitive effects.
- Unmeasured Cognitive Domains: The study did not assess autobiographical memory or executive function, which are known to be affected by ECT.
- Heterogeneity of Indications: The study included patients with various indications for seizure therapy, which could influence outcomes.
Future research should focus on:
- Larger Sample Sizes: To confirm findings and conduct more robust statistical analyses.
- Longer Follow-up Periods: To better understand the long-term cognitive and clinical effects of MST.
- Specific Patient Populations: Investigating MST in patients with specific indications for seizure therapy and those with comorbid conditions.
- Less Cognition-Affecting ECT Techniques: Comparing MST to newer, less cognitively impairing forms of ECT (e.g., ultrabrief pulse, unilateral placement).
- Optimal MST Parameters: Further research into the optimal parameters (coil placement, pulse frequency, treatment frequency) for MST in schizophrenia.
- Measuring Additional Cognitive Domains: Including assessments for autobiographical memory and executive function.
Summary updated